Your browser doesn't support javascript.
loading
Triglyceride-lowering LPL alleles combined with LDL-C-lowering alleles are associated with an additively improved lipoprotein profile.
Ibi, Dorina; Blauw, Lisanne L; Noordam, Raymond; Dollé, Martijn E T; Jukema, J Wouter; Rosendaal, Frits R; Christodoulides, Constantinos; Neville, Matt J; Koivula, Robert; Rensen, Patrick C N; Karpe, Fredrik; van Dijk, Ko Willems.
Afiliación
  • Ibi D; Dept. Human Genetics, Leiden University Medical Center, Leiden, the Netherlands; Dept. Public Health and Primary Care, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. Electronic address: d.ibi@lumc.nl.
  • Blauw LL; Dept. Internal Medicine, Div. Endocrinology, Leiden University Medical Center, Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands.
  • Noordam R; Dept. Internal Medicine, Div. Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands.
  • Dollé MET; Dept. Public Health and Primary Care, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Jukema JW; Dept. Cardiology, Leiden University Medical Center, Leiden, the Netherlands.
  • Rosendaal FR; Dept. Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
  • Christodoulides C; Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Neville MJ; Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals Foundation Trust, Oxford, United Kingdom.
  • Koivula R; Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Rensen PCN; Dept. Internal Medicine, Div. Endocrinology, Leiden University Medical Center, Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands.
  • Karpe F; Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals Foundation Trust, Oxford, United Kingdom.
  • van Dijk KW; Dept. Human Genetics, Leiden University Medical Center, Leiden, the Netherlands; Dept. Internal Medicine, Div. Endocrinology, Leiden University Medical Center, Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Atherosclerosis ; 328: 144-152, 2021 07.
Article en En | MEDLINE | ID: mdl-34053745
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Lipasa / Lipoproteína Lipasa Tipo de estudio: Clinical_trials / Risk_factors_studies País/Región como asunto: Europa Idioma: En Revista: Atherosclerosis Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Lipasa / Lipoproteína Lipasa Tipo de estudio: Clinical_trials / Risk_factors_studies País/Región como asunto: Europa Idioma: En Revista: Atherosclerosis Año: 2021 Tipo del documento: Article